Small Interfering Ribonucleic Acid (siRNA)-Based Therapeutics in Inflammatory Bowel Disease: Crosstalk between Immune...

Area of Science:

• Gastroenterology
• Immunology
• RNA Therapeutics

Background:

• Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, involves immune dysregulation, barrier dysfunction, and microbial imbalance.
• Current IBD treatments like corticosteroids, immunomodulators, and biologics have limitations including nonspecific action, side effects, and suboptimal remission rates.

Purpose of the Study:

• To review recent advancements in small interfering RNA (siRNA) therapies for IBD.
• To explore siRNA's potential in immune modulation and epithelial barrier restoration for IBD treatment.

Main Methods:

• Review of current literature on siRNA applications in IBD.
• Analysis of siRNA's mechanisms targeting inflammatory pathways and mucosal barrier integrity.

Main Results:

• siRNA effectively silences genes encoding proinflammatory cytokines (e.g., TNF-α, IL-6) and signaling pathways (e.g., NF-κB, JAK/STAT).
• siRNA enhances mucosal barrier function by targeting tight junction proteins (e.g., ZO-1, occludin).
• Combination siRNA therapies show promise for IBD management.

Conclusions:

• siRNA represents a precision-driven therapeutic strategy for IBD with potential for immune modulation and barrier repair.
• Further clinical translation is necessary to establish the safety and efficacy of siRNA therapies for IBD.